Fig. 8

DRD2 agonist treatment attenuates central sensitization via the PI3K signaling pathway. A, B and C The PI3K activator 740YP reversed the anti-injury effects of the DRD2 agonist quinpirole and reduced pain thresholds in CM rats. Two-way ANOVA with the Bonferroni post hoc test; n = 6/group; **P < 0.01, ***P < 0.001 vs. the Sham + DMSO group; ###P < 0.001 vs. the CM + DMSO group. D and E 740YP reversed the DRD2-mediated reductions in the protein expression of PSD95 and phosphorylation of ERK. F and G 740YP abolished the effects of the DRD2 agonist on reducing GLUA1 membrane trafficking and p-GLUA1 levels. One-way ANOVA with Dunnett’s post hoc test; n = 6/group; **P < 0.01, ***P < 0.001 vs. the Sham + DMSO group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. the CM + DMSO group